cetuximab

1
Reactions 1412 - 28 Jul 2012 S Cetuximab Hypomagnesaemia: 5 case reports Two women and three men aged 56–78 years developed grade 3–4 hypomagnesaemia after starting cetuximab for metastatic colorectal cancer [route not stated; dosages not clearly stated]. They were identified as part of a retrospective analysis of routine monitoring of serum magnesium levels in patients receiving cytotoxic chemotherapy. All five patients developed grade 3 hypomagnesaemia 35–280 days after starting cetuximab; two progressed to grade 4 hypomagnesaemia after 175 and 273 days, respectively. The patients’ lowest serum magnesium levels were 0.24–0.37 mmol/L. Duration of cetuximab therapy * ranged from 10 to 45 weeks. No major clinical symptoms attributable to low serum magnesium levels were noted in the five patients; however, grade 1 fatigue was reported in one woman. All five patients also had serum calcium levels below the lower limit of normal; the lowest serum calcium levels ranged from 1.32 to 1.85 mmol/L. Serum potassium levels were 2.7–4.8 mmol/L. Survival from the start of treatment ranged from 3 to 33 months for the five patients. Author comment: "[A]symptomatic hypomagnesaemia is common in metastatic colorectal carcinoma patients treated with cetuximab. . . Serum magnesium should be routinely assessed in cancer patients treated with new agents, specifically with agents targeting [epidermal growth factor receptor]." * Most patients in the retrospective analysis received cetuximab (loading dose of 400 mg/m 2 then 250 mg/m 2 weekly), irinotecan, folinic acid [leucovorin] and fluorouracil; however, one patient received a modified version of this regimen, one received the regimen with irinotecan omitted and one patient received cetuximab monotherapy. Melichar B, et al. Hypomagnesaemia in patients with metastatic colorectal carcinoma treated with cetuximab. Hepato-Gastroenterology 59: 366-371, No. 114, Apr 2012. Available from: URL: http://dx.doi.org/10.5754/hge10330 - Czech Republic 803074295 1 Reactions 28 Jul 2012 No. 1412 0114-9954/10/1412-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Upload: nguyentruc

Post on 17-Mar-2017

224 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Cetuximab

Reactions 1412 - 28 Jul 2012

SCetuximab

Hypomagnesaemia: 5 case reportsTwo women and three men aged 56–78 years developed

grade 3–4 hypomagnesaemia after starting cetuximab formetastatic colorectal cancer [route not stated; dosages notclearly stated]. They were identified as part of aretrospective analysis of routine monitoring of serummagnesium levels in patients receiving cytotoxicchemotherapy.

All five patients developed grade 3 hypomagnesaemia35–280 days after starting cetuximab; two progressed tograde 4 hypomagnesaemia after 175 and 273 days,respectively. The patients’ lowest serum magnesium levelswere 0.24–0.37 mmol/L. Duration of cetuximab therapy*

ranged from 10 to 45 weeks. No major clinical symptomsattributable to low serum magnesium levels were noted inthe five patients; however, grade 1 fatigue was reported inone woman. All five patients also had serum calcium levelsbelow the lower limit of normal; the lowest serum calciumlevels ranged from 1.32 to 1.85 mmol/L. Serum potassiumlevels were 2.7–4.8 mmol/L. Survival from the start oftreatment ranged from 3 to 33 months for the five patients.

Author comment: "[A]symptomatic hypomagnesaemia iscommon in metastatic colorectal carcinoma patientstreated with cetuximab. . . Serum magnesium should beroutinely assessed in cancer patients treated with new agents,specifically with agents targeting [epidermal growth factorreceptor]."

* Most patients in the retrospective analysis received cetuximab(loading dose of 400 mg/m2 then 250 mg/m2 weekly), irinotecan,folinic acid [leucovorin] and fluorouracil; however, one patientreceived a modified version of this regimen, one received theregimen with irinotecan omitted and one patient receivedcetuximab monotherapy.

Melichar B, et al. Hypomagnesaemia in patients with metastatic colorectalcarcinoma treated with cetuximab. Hepato-Gastroenterology 59: 366-371, No. 114,Apr 2012. Available from: URL: http://dx.doi.org/10.5754/hge10330 - CzechRepublic 803074295

1

Reactions 28 Jul 2012 No. 14120114-9954/10/1412-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved